Anti-HIV-1 Activity of Combinations and Covalent Conjugates of Negatively Charged Human Serum Albumins (NCAs) and AZT

References

• Ames G. F.-L., Lecar H. ATP-dependent bacterial transporters and cystic fibrosis: Analogy between channels and transporters. FASEB J. 1992; 6: 2660–2666
   PubMed Web of Science ®Google Scholar
• Anand R., Nayyar S., Galvin T. A., Merril C. R., Bigelow L. B. Sodium pentosan polysulfate (PPS), an anti-HIV agent also exhibits synergism with AZT, lymphoproliferative activity, and virus enhancement. AIDS Res. Hum. Retroviruses 1990; 6: 679–689
   PubMed Web of Science ®Google Scholar
• Baba M., Ito M., Shigeta S., De Clercq E. Synergistic antiviral effects of antiherpes compounds and human leukocyte interferon on varicella-zoster virus in vitro. Antimicrob. Agents Chemother. 1984; 25: 515–517
   PubMed Web of Science ®Google Scholar
• Baba M., Schols D., Pauwels R., Nakashima H., De Clercq E. Sulfated polysaccharides as potent inhibitors of HIV-induced syncytium formation: a new strategy towards AIDS chemotherapy. J. Acquir. Immune Defic. Syndr. 1990; 3: 493–499
   PubMed Web of Science ®Google Scholar
• Bergeron L., Sullivan N., Sodroski J. Target cell-specific determinants of membrane fusion within the human immunodeficiency virus type 1 gp 120 third variable region and gp41 amino terminus. J. Virol 1992; 66: 2389–2397
   PubMed Web of Science ®Google Scholar
• Borman A. M., Paulous S., Gavel F. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 1996; 77: 419–426
   PubMed Web of Science ®Google Scholar
• Breen E. C., Rezai A. R., Nakajima K., Beall G. N., Mitsuyasu R. T., Hirano T., Kishimoto T., Martinez Maza O. Infection with HIV is associated with elevated IL-6 levels and production. J. Immunol. 1990; 144: 480–484
   PubMed Web of Science ®Google Scholar
• Brighty D. W., Rosenberg M., Chen I. S., IveyHoyle M. Envelope proteins from clinical isolates of human immunodeficiency virus type 1 that are refractory to neutralization by soluble CD4 possess high affinity for the CD4 receptor. Proc. Natl. Acad. Sci. USA 1991; 88: 7802–7805
   PubMed Web of Science ®Google Scholar
• Collier A. C., Coombs R. W., Schoenfeld D. A., Bassett R. L., Timpone J., Baruch A., Jones M., Facey K., Whitacre C., McAuliffe V. J., Friedman H. M., Merigan T. C., Reichman R. C., Hooper C., Corey L. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. N. Engl. J. Med. 1996; 334: 1011–1017
   PubMed Web of Science ®Google Scholar
• De Clercq E. Perspectives for the chemotherapy of AIDS. Anticancer Res. 1987; 7: 1023–1038
   PubMed Web of Science ®Google Scholar
• De Clercq E., Yamamoto N., Pauwels R., Baba M., Schols D., Nakashima H., Balzarini J., Debyser Z., Murrer B. A., Schwartz D., Thornton D., Bridger G., Fricker S., Henson G., Abrams M., Picker D. Potent and selective inhibition of human immunodeficiency virus (HIV)-l and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc. Natl. Acad. Sci. USA 1992; 89: 5286–5290
   PubMed Web of Science ®Google Scholar
• De Clercq E. Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 1995; 8: 200–239
   PubMed Web of Science ®Google Scholar
• Dimitrov D. S., Blumenthal R. Photoinactivation and kinetics of membrane fusion mediated by the human immunodeficiency virus type 1 envelope glycoprotein. J. Virol. 1994; 68: 1956–1961
   PubMed Web of Science ®Google Scholar
• Elion G. B., Singer S., Hitchings G. H. Antagonists of nucleic acid derivatives VIII. Synergism in combination of biochemically related antimetabolites. J. Biol. Chem. 1954; 208: 477–488
   PubMed Web of Science ®Google Scholar
• Fitzgibbon J. E., Howell R. M., Haberzettl C. A., Sperber S. J., Gocke D. J., Dubin D. T. Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. Antimicrob. Agents Chemother. 1992; 36: 153–157
   PubMed Web of Science ®Google Scholar
• Gordon L. M., Waring A. J., Curtain C. C., Kirkpatrick A., Leung C., Faull K., Mobley P. W. Antivirals that target the amino-terminal domain of HIV type 1 glycoprotein 41. AIDS Res. Hum. Retroviruses 1995; 11: 677–686
   PubMed Web of Science ®Google Scholar
• Groenink M., Swart P. J., Broersen S., Kuipers M. E., Meijer D. K.F., Schuitemaker H. Potent inhibition of replication of primary HIV-1 isolates by negatively charged human serum albumin. AIDS Res. Hum. Retroviruses 1997; 13: 179–185
   PubMed Web of Science ®Google Scholar
• Habeeb A. F.S.A. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal. Biochem. 1966; 14: 328–336
   PubMed Web of Science ®Google Scholar
• Halloran M. J., Parker C. W. The preparation of nucleotide-protein conjugates: carbodiimides as coupling agents. J. Immunol. 1966; 96: 373–378
   PubMed Web of Science ®Google Scholar
• Haseltine W. A. Replication and pathogenesis of the AIDS virus. J. Acquir. Immune. Defic. Syndr. 1988; 1: 217–240
   PubMed Web of Science ®Google Scholar
• Hayashi S., Fine R. L., Chou T. C., Currens M. J., Broder S., Mitsuya H. In vitro inhibition of the infectivity and replication of human immunodeficiency virus type-1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors. Antimicrob. Agents Chemother. 1990; 34: 82–88
   PubMed Web of Science ®Google Scholar
• Jansen R. W., Molema G., Pauwels R., Schols D., De Clercq E., Meijer D. K.F. Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins. Mol. Pharmacol. 1991; 39: 818–823
   PubMed Web of Science ®Google Scholar
• Jansen R. W., Olinga P., Harms G., Meijer D. K.F. Pharmacokinetic analysis and cellular distribution of the anti-HIV compound succinylated human serum albumin (Suc-HSA) in vivo and in the isolated perfused rat liver. Pharm. Res. 1993a; 10: 1611–1614
   PubMed Web of Science ®Google Scholar
• Jansen R. W., Schols D., Pauwels R., De Clercq E., Meijer D. K.F. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity. Mol. Pharmacol. 1993b; 44: 1003–1007
   PubMed Web of Science ®Google Scholar
• Katzenstein D. A., Holodniy M. HIV viral load quantification, HIV resistance, and antiretroviral therapy. AIDS Clin. Rev. 1995; 1995–1996: 277–303
   Google Scholar
• Kennedy C. J. AZT in the treatment of AIDS and ARC. HIV and Other Highly Pathogenic Viruses, R. A. Smith. Academic Press, Inc., Harcourt Brace Jovanovich, Publishers, San Diego, New York, Berkeley, Boston, London, Sydney, Tokyo, Toronto 1987; 81–93
   Google Scholar
• Kuipers M. E., Swart P. J., Hendriks M. M.W.B., Meijer D. K.F. Optimization of the reaction conditions for the synthesis of neoglycoprotein-AZT-monophosphate conjugates. J. Med. Chem. 1995; 38: 883–889
   PubMed Web of Science ®Google Scholar
• Kuipers M. E., Huisman J. G., Swart P. J., de Béthune M., Pauwels R., De Clercq E., Schuitemaker H., Meijer D. K.F. Mechanism of anti-HIV activity of negatively charged albumins: biomolecular interaction with the HIV-1 envelope protein gp120. J. Acq. Immun. Defic. Synd. Hum. R. 1996a; 11: 419–429
   PubMedGoogle Scholar
• Kuipers M. E., Swart P. J., Smit C., Meijer D. K.F. Binding of negatively charged human serum albumins to lymphocytes: implications for shielding of HIV-1 binding and fusion. Thesis Biomolecular and pharmacokinetic studies on drug delivery preparations with dual activity on HIV-1, University of Groningen, The Netherlands 1996b, ISBN 90-90009738-4. Chapter 4.
   Google Scholar
• Kuipers M. E., Swart P. J., Schutten M., Smit C., Osterhaus A. D.M.E., Meijer D. K.F. Pharmacokinetics and anti-hiv-1 efficacy of negatively charged human serum albumins in mice. Antiviral Res. 1997; 33: 99–108
   PubMed Web of Science ®Google Scholar
• Lafeuillade A., Poggi C., Tamalet C., Profizi N., Tourres C., Costes O. Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. J. Infect. Dis. 1997; 175: 1051–1055
   PubMed Web of Science ®Google Scholar
• Lambert D. M., Bartus H., Fernandez A. V., Bratby-Anders C., Leary J. J., Dreyer G. B., Metcalf B. W., Petteway S. R., Jr. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection. Antiviral Res. 1993; 21: 327–342
   PubMed Web of Science ®Google Scholar
• Larder B. A., Darby G., Richman D. D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989; 243: 1731–1734
   PubMed Web of Science ®Google Scholar
• Larder B. A., Kemp S. D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246: 1155–1158
   PubMed Web of Science ®Google Scholar
• Lifson J. D., Feinberg M. B., Reyes G. R., Rabin L., Banapour B., Chakrabarti S., Moss B., Wong Staal F., Steimèr K. S., Engleman E. G. Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein. Nature 1986; 323: 725–728
   PubMed Web of Science ®Google Scholar
• Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• Machida A., Kishimoto S., Ohnuma H., Baba K., Ito Y., Miyamoto H., Funatsu G., Oda K., Usuda S. T.S, Nakamura T., Miyakawa Y., Mayumi M. A polypeptide containing 55 amino acid residues coded by the pre-S region of hepatitis B virus deoxyribonucleic acid bears the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology 1984; 86: 910–918
   PubMed Web of Science ®Google Scholar
• Meng T.-C., Fischl M. A., Boota A. M., Spector S. A., Bennett D., Bassiakos Y., Lai S., Wright B., Richman D. D. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann. Intern. Med. 1992; 116: 13–20
   PubMed Web of Science ®Google Scholar
• Meshcheryakova D., Andreev S., Tarasova S., Sidorova M., Vafina M., Kornilaeva G., Karamov E., Khaitov R. CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp120 fragments. Mol. Immunol. 1993; 30: 993–1001
   PubMed Web of Science ®Google Scholar
• Molema G., Jansen R. W., Pauwels R., De Clercq E., Meijer D. K.F. Targeting of antiviral drugs to T-4 lymphocytes: Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro. Biochem. Pharmacol. 1990; 40: 2603–2610
   PubMed Web of Science ®Google Scholar
• Molema G., Jansen R. W., Visser J., Herdewijn P., Moolenaar F., Meijer D. K.F. Neoglycoproteins as carriers for antiviral drugs: synthesis and analysis of protein-drug conjugates. J. Med. Chem. 1991; 34: 1137–1141
   PubMed Web of Science ®Google Scholar
• Molema G. Delivery of the anti-HIV drug azidothymidine (AZT) to T-lymphocytes with neoglycoprotein carriers. Thesis: Delivery of the anti-HIV drug azidothymidine (AZT) to T-lymphocytes with neoglycoprotein carriers, University Groningen, The Netherlands 1992, ISBN 90-90005402-2. Chapter 6
   Google Scholar
• Molla A., Korneyeva M., Gao Q., Vasavanonda S., Schipper P. J., Mo H. M., Markowitz M., Chernyavskiy T., Niu P., Lyons N., Hsu A., Granneman G. R., Ho D. D., Boucher C. A., Leonard J. M., Norbeck D. W., Kempf D. J. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 1996; 2: 760–766
   PubMed Web of Science ®Google Scholar
• Moyle G., Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996; 51: 701–712
   PubMed Web of Science ®Google Scholar
• Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., De Clercq E. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988; 20: 309–321
   PubMed Web of Science ®Google Scholar
• Pinter A., Honnen W. J., Tilley S. A. Conformational changes affecting the V3 and CD4-binding domains of human immunodeficiency virus type 1 gp120 associated with env processing and with binding of ligands to these sites. J. Virol. 1993; 67: 5692–5697
   PubMed Web of Science ®Google Scholar
• Schols D., Pauwels R., Desmyter J., De Clercq E. Dextran sulfate and other polyanionic anti-HIV compounds specifically interact with the viral gp120 glycoprotein expressed by the T-cells persistently infected with HIV-1. Virology 1990; 175: 556–561
   PubMed Web of Science ®Google Scholar
• St. Clair M. H., Hartigan P. M., Andrews J. C., Vavro C. L., Simberkoff M. S., Hamilton J. D. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group. J. Acquir. Immune. Defic. Syndr. 1993; 6: 891–897
   PubMed Web of Science ®Google Scholar
• St. Clair M. H., Martin J. L., Tudor-Williams G., Bach M. C., Vavro C. L., King D. M., Kellam P., Kemp S. D., Larder B. A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253: 1557–1559
   PubMed Web of Science ®Google Scholar
• Swart P. J., Schutten M., Smit C., Van Amerongen G., Proost J. H., Osterhaus A. D.M.E., Meijer D. K.F. Pharmacokinetics of succinylated serum albumin in wistar rats and cynomolgus monkeys: implications for dosage regiments in the therapy of HIV-infection. Drug Delivery 1996a; 3: 165–171
   PubMedGoogle Scholar
• Swart P. J., Smit C., Pasma A., Beljaars E., Schuitemaker H., Meijer D. K.F. Comparative pharmacokinetics, immunologic and hematologic studies on the anti-HIV-1/-2 compouds succinylated and aconitylated HSA. Journal of Drug Targeting 1996b; 4: 109–116
   PubMed Web of Science ®Google Scholar
• Swart P. J., Meijer D. K.F. Negatively-charged albumins: A novel class of polyanionic proteins with a potent anti-HIV activity. Antiviral News 1994; 2: 69–71
   Google Scholar
• Tisdale M., Myers R. E., Maschera B., Parry N. R., Oliver N. M., Blair E. D. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 1995; 39: 1704–1710
   PubMed Web of Science ®Google Scholar
• Ueno R., Kuno S. Dextran sulphate, a potent anti-HIV agent in vitro having synergism with zidovudine (letter). Lancet 1987; 1: 1379, Jun. 13(8546)
   PubMed Web of Science ®Google Scholar
• van 't Wout A. B., Ran L. J., de Jong M. D., Bakker M., van Leeuwen R., Notermans D. W., Loeliger A. E., De Wolf F., Danner S. A., Reiss P., Boucher C. A., Lange J. M.A., Schuitemaker H. Selective inhibition of syncytium inducing and non-syncytium inducing HIV-1 variants in individuals receiving didanosine or zidovudine respectively. J. Clin. Invest. 1997; 100: 2325–2332
   PubMed Web of Science ®Google Scholar
• Vella S. Rationale and experience with reverse transcriptase inhibitors and protease inhibitors. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 1995; 10: S58–S61
   PubMedGoogle Scholar
• Wilde M. I., Langtry H. D. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1993; 46: 515–578
   PubMed Web of Science ®Google Scholar
• Witvrouw M., Desmyter J., De Clercq E. Antiviral portrait series: 4. Polysulfates as inhibitors of HIV and other enveloped viruses. Antiviral Chem. Chemother. 1994; 5: 345–359
   Web of Science ®Google Scholar